Anzeige
Mehr »
Donnerstag, 17.07.2025 - Börsentäglich über 12.000 News
Klinisch validiert. Vertriebsbereit. Und kurz vor der FDA-Zulassung.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AJ68 | ISIN: NL0011832936 | Ticker-Symbol: C43
Tradegate
17.07.25 | 13:03
65,50 Euro
-2,96 % -2,00
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
COSMO PHARMACEUTICALS NV Chart 1 Jahr
5-Tage-Chart
COSMO PHARMACEUTICALS NV 5-Tage-Chart
RealtimeGeldBriefZeit
65,5066,0014:06
65,5066,0013:04

Aktuelle News zur COSMO PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07:14Cosmo Pharmaceuticals N.V.: Cosmo Announces Launch of Winlevi(R) for Treatment of Acne in Singapore and Malaysia247Dublin, Ireland--(Newsfile Corp. - July 17, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, is pleased to announce the launch...
► Artikel lesen
MiCosmo Pharmaceuticals N.V.: Cosmo Accelerates Global ESG Leadership with Major Ratings Upgrades, UN Compact Commitment, and Climate Action Pledge292Dublin, Ireland--(Newsfile Corp. - July 16, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced a major leap forward in...
► Artikel lesen
01.07.Cosmo setzt sich am Investorentag ehrgeizige Finanzziele bis 2030317Dublin - Das Life-Science-Unternehmen Cosmo nimmt seinen Investorentag zum Anlass, Finanzziele für die kommenden fünf Jahre zu bestimmen. Sowohl für den Umsatz als auch die EBITDA-Marge setzt sich das...
► Artikel lesen
01.07.Cosmo Pharmaceuticals N.V.: Cosmo Unveils Bold 2030 Vision and Strategy; Launches AI-Driven Growth Phase at Investor Day 2025390Ad hoc announcement pursuant to Art. 53 LR Company sets ambitious vision for €480 million in recurring revenues and a 40% EBITDA margin by 2030; outlines roadmap for accelerated AI-driven...
► Artikel lesen
25.06.Cosmo Pharmaceuticals N.V.: Cosmo Announces Sale of "Digital Trust" in Strategic Portfolio Streamlining Move366Dublin, Ireland--(Newsfile Corp. - June 25, 2025) - Cosmo today announced the signing of an agreement to sell "Digital Trust" to its existing customer Tinexta InfoCert, Europe's largest Certification...
► Artikel lesen
24.06.Cosmo Pharmaceuticals N.V.: Cosmo to Unveil First-of-its-Kind Clinical Study on the Use of GI Genius with Apple Vision Pro at Rush University Medical Center415Dublin, Ireland--(Newsfile Corp. - June 24, 2025) - Cosmo Pharmaceuticals N.V. ("Cosmo") today announced that in July 2025, it will initiate their first usability study of a medical device software...
► Artikel lesen
04.06.Dividendenbekanntmachungen (04.06.2025)10.138 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  ADESSO SE  DE000A0Z23Q5 - 0,75 EUR  AGEAS SA/NV  BE0974264930 - 2 EUR  AIR LEASE CORPORATION  US00912X3026  0,22 USD  0,1934 EUR  ANALOG...
► Artikel lesen
30.05.Cosmo Pharmaceuticals N.V.: Voting Results of Cosmo's 2025 AGM471Dublin, Ireland--(Newsfile Corp. - May 30, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") announced that its shareholders approved all voting items at today's Ordinary Annual...
► Artikel lesen
COSMO PHARMACEUTICALS Aktie jetzt für 0€ handeln
05.05.Cosmo Pharmaceuticals N.V.: Cosmo Highlights Strategic AI and GI Innovation Agenda at Digestive Disease Week(R) 2025496Dublin, Ireland--(Newsfile Corp. - May 5, 2025) - Cosmo is attending this year's Digestive Disease Week® (DDW), held in San Diego, California from May 3-6, where its leadership team is advancing...
► Artikel lesen
02.05.Cosmo Pharmaceuticals N.V.: Cosmo Announces EU MDR Certification for Endovision's Cerebro, expanding its real-time AI ecosystem602Dublin, Ireland--(Newsfile Corp. - May 2, 2025) - Cosmo is excited to announce that Endovision Limited, a leading innovator in endoscopic imaging solutions, has received EU MDR certification[1]...
► Artikel lesen
30.04.XETR DELETION OF INSTRUMENTS FROM XETRA - 30.04.2025993The following instruments on XETRA do have their last trading day on 30.04.2025.Die folgenden Instrumenteauf XETRA haben ihren letzten Handelstag am 30.04.2025.ISIN NameNL0011832936 Cosmo Pharmaceuticals...
► Artikel lesen
29.04.Cosmo Pharmaceuticals N.V.: Cosmo Pharmaceuticals Confirms Financial Guidance Following CHMP Opinion on Winlevi(R)490Dublin, Ireland--(Newsfile Corp. - April 29, 2025) - Following the recent CHMP opinion regarding the marketing authorization application for Winlevi® (clascoterone cream 1%) in Europe, Cosmo Pharmaceuticals...
► Artikel lesen
29.04.Cosmo Pharmaceuticals N.V.: Cosmo Receives Negative CHMP Opinion on Winlevi(R) (clascoterone Cream 1%) in Europe and Will Appeal the Decision436Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - April 29, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) announces that the Committee for Medicinal Products for...
► Artikel lesen
29.04.Cosmo Pharmaceuticals N.V.: Cosmo Publishes Agenda of AGM 2025615Dublin, Ireland--(Newsfile Corp. - April 29, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo" or the "Company") today announced the convening of its Annual General Meeting 2025...
► Artikel lesen
01.04.Cosmo Pharmaceuticals N.V.: Cosmo Appoints Federico Sommariva as Chief Legal Counsel483Dublin, Ireland--(Newsfile Corp. - April 1, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") today announced the appointment of Federico Sommariva ad Chief Legal Counsel. Federico...
► Artikel lesen
21.03.Cosmo Pharmaceuticals reports FY results11
21.03.Cosmo Pharmaceuticals N.V.: Cosmo Pharmaceuticals publishes Annual Report 2024552Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - March 21, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") has published today its Annual Report...
► Artikel lesen
06.03.Cosmo Pharmaceuticals N.V. reports FY results13
06.03.Cosmo wächst dank Schlüsselprodukten 2024 weiter480Dublin - Das Spezialitätenpharma-Unternehmen Cosmo hat 2024 einen Gewinnsprung verzeichnet. Der Umsatz hat sich derweil nahezu verdreifacht, wie das Unternehmen bereits Anfang Januar gemeldet hatte....
► Artikel lesen
06.03.Cosmo Pharmaceuticals N.V.: Cosmo Pharmaceuticals Delivers Record 2024 Results - Completes Phase III Enrollment for Androgenetic Alopecia in Males - Proposes Increased Dividend of 2.05 per share - Reinforcing Shareholder Value and Growth Momentum into 202642Ad hoc announcement pursuant to Art. 53 LR FY 2024 Revenue of €266.8 million (unaudited) reaching upper end of guidance FY 2024 Operating Profit (unaudited) of €148.9 million...
► Artikel lesen
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1